Home / Investors Information / EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate Cancer Read more about EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate Cancer EDAP to Ring the NASDAQ Stock Market Closing Bell On Dec. 17 Read more about EDAP to Ring the NASDAQ Stock Market Closing Bell On Dec. 17 EDAP Retains The Ruth Group as Investor Relations Counsel Read more about EDAP Retains The Ruth Group as Investor Relations Counsel EDAP Adds Sites in Phase II/III Ablatherm-HIFU Clinical Trial for Localized Prostate Cancer Read more about EDAP Adds Sites in Phase II/III Ablatherm-HIFU Clinical Trial for Localized Prostate Cancer EDAP Launches First Sonolith I-Sys Unit in Europe Read more about EDAP Launches First Sonolith I-Sys Unit in Europe EDAP TMS S.A. Reports 2007 Fourth Quarter and Year End Preliminary Unaudited Revenues Read more about EDAP TMS S.A. Reports 2007 Fourth Quarter and Year End Preliminary Unaudited Revenues EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference Read more about EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference EDAP Reports Publication of Head-to-Head Study of Ablatherm-HIFU Versus Other HIFU Technology for Prostate Cancer Read more about EDAP Reports Publication of Head-to-Head Study of Ablatherm-HIFU Versus Other HIFU Technology for Prostate Cancer EDAP's HIFU Technology Highlighted At Three Prestigious U.S. Medical Conferences Read more about EDAP's HIFU Technology Highlighted At Three Prestigious U.S. Medical Conferences Edap Highlights Ablatherm Munich-based Harlaching Hospital as the Leading Treatment Center in 2007 Read more about Edap Highlights Ablatherm Munich-based Harlaching Hospital as the Leading Treatment Center in 2007 Pagination First page « First Previous page ‹ Previous … Page 48 Page 49 Page 50 Page 51 Page 52 Page 53 Current page 54 Page 55 Page 56 Next page Next › Last page Last » Subscribe to
EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate Cancer Read more about EDAP Announces First Published Long-Term Study of HIFU for Localized Prostate Cancer
EDAP to Ring the NASDAQ Stock Market Closing Bell On Dec. 17 Read more about EDAP to Ring the NASDAQ Stock Market Closing Bell On Dec. 17
EDAP Retains The Ruth Group as Investor Relations Counsel Read more about EDAP Retains The Ruth Group as Investor Relations Counsel
EDAP Adds Sites in Phase II/III Ablatherm-HIFU Clinical Trial for Localized Prostate Cancer Read more about EDAP Adds Sites in Phase II/III Ablatherm-HIFU Clinical Trial for Localized Prostate Cancer
EDAP Launches First Sonolith I-Sys Unit in Europe Read more about EDAP Launches First Sonolith I-Sys Unit in Europe
EDAP TMS S.A. Reports 2007 Fourth Quarter and Year End Preliminary Unaudited Revenues Read more about EDAP TMS S.A. Reports 2007 Fourth Quarter and Year End Preliminary Unaudited Revenues
EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference Read more about EDAP TMS SA to Present at Roth 20th Annual OC Growth Stock Conference
EDAP Reports Publication of Head-to-Head Study of Ablatherm-HIFU Versus Other HIFU Technology for Prostate Cancer Read more about EDAP Reports Publication of Head-to-Head Study of Ablatherm-HIFU Versus Other HIFU Technology for Prostate Cancer
EDAP's HIFU Technology Highlighted At Three Prestigious U.S. Medical Conferences Read more about EDAP's HIFU Technology Highlighted At Three Prestigious U.S. Medical Conferences
Edap Highlights Ablatherm Munich-based Harlaching Hospital as the Leading Treatment Center in 2007 Read more about Edap Highlights Ablatherm Munich-based Harlaching Hospital as the Leading Treatment Center in 2007
